Mittie Doyle - Jul 15, 2024 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Medical Officer
Signature
/s/ Donald R. Reynolds, by Power of Attorney
Stock symbol
AVTX
Transactions as of
Jul 15, 2024
Transactions value $
$0
Form type
4
Date filed
7/16/2024, 04:23 PM
Previous filing
Aug 9, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Award $0 +234K $0.00 234K Jul 15, 2024 Common Stock 234K $12.65 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the Option Shares vest on July 15, 2025 and the remainder of the Option Shares will vest in equal monthly installments over the following three (3) years, provided that Optionee remains an employee of the Company on each such vesting date.